# Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

> **NCT02670915** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 834 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Faster-acting insulin aspart
- **DRUG:** insulin aspart
- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT02670915
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-04
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-03-03
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670915, "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02670915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*